Spectrum Pharmaceuticals Inc
SPPI
SPPIは2023年7月31日に上場廃止となりました。
概要： Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations. It has one segment that is focused exclusively on developing and marketing oncology and hematology drug products.
従業員数： 86
ニュース
SPPIに関する最近のニュース記事はまだ届いていません。